ARQT / Arcutis Biotherapeutics: Market Discounting Zoryve Momentum

Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, more_horizontal

The heavy selling pressure might have exhausted for Arcutis Biotherapeutics, Inc. (ARQT) as it is technically in oversold territory now. In addition t more_horizontal

Arcutis will host a conference call and webcast at 8:30 a.m. ET on 11/3/2023 to report its third quarter financial results and provide a business upda more_horizontal

Arcutis Biotherapeutics Inc shares slid more than 18% in pre-market trading on Friday after the early commercial-stage medical dermatology company ann more_horizontal

Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years more_horizontal

Arcutis (ARQT) submits sNDA, seeking label expansion of Zoryve (roflumilast) cream 0.15% to treat patients with atopic dermatitis. more_horizontal

Arcutis' cash position is the biggest concern for investors. The company is already seeing strong sales from Zoryve, a little more than a year after i more_horizontal

Here's a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential more_horizontal